JP2012092123A5 - - Google Patents

Download PDF

Info

Publication number
JP2012092123A5
JP2012092123A5 JP2011272494A JP2011272494A JP2012092123A5 JP 2012092123 A5 JP2012092123 A5 JP 2012092123A5 JP 2011272494 A JP2011272494 A JP 2011272494A JP 2011272494 A JP2011272494 A JP 2011272494A JP 2012092123 A5 JP2012092123 A5 JP 2012092123A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
use according
administered
composition
brimonidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011272494A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012092123A (ja
Filing date
Publication date
Priority claimed from US10/607,439 external-priority patent/US20040266776A1/en
Application filed filed Critical
Publication of JP2012092123A publication Critical patent/JP2012092123A/ja
Publication of JP2012092123A5 publication Critical patent/JP2012092123A5/ja
Pending legal-status Critical Current

Links

JP2011272494A 2003-06-25 2011-12-13 ストレス関連症状の重症性を軽減し予防する方法 Pending JP2012092123A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/607,439 US20040266776A1 (en) 2003-06-25 2003-06-25 Methods of preventing and reducing the severity of stress-associated conditions
US10/607,439 2003-06-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006517594A Division JP2007524625A (ja) 2003-06-25 2004-06-22 ストレス関連症状の重症性を軽減し予防する方法

Publications (2)

Publication Number Publication Date
JP2012092123A JP2012092123A (ja) 2012-05-17
JP2012092123A5 true JP2012092123A5 (enExample) 2012-12-27

Family

ID=33540268

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006517594A Pending JP2007524625A (ja) 2003-06-25 2004-06-22 ストレス関連症状の重症性を軽減し予防する方法
JP2011272494A Pending JP2012092123A (ja) 2003-06-25 2011-12-13 ストレス関連症状の重症性を軽減し予防する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006517594A Pending JP2007524625A (ja) 2003-06-25 2004-06-22 ストレス関連症状の重症性を軽減し予防する方法

Country Status (14)

Country Link
US (6) US20040266776A1 (enExample)
EP (1) EP1638569B1 (enExample)
JP (2) JP2007524625A (enExample)
KR (1) KR20060023575A (enExample)
CN (2) CN102579448A (enExample)
AT (1) ATE539751T1 (enExample)
AU (2) AU2004253500A1 (enExample)
BR (1) BRPI0411826A (enExample)
CA (1) CA2530487C (enExample)
DK (1) DK1638569T3 (enExample)
ES (1) ES2376878T3 (enExample)
MX (1) MXPA05013900A (enExample)
TW (1) TWI371276B (enExample)
WO (1) WO2005002580A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
WO2002043785A2 (en) 2000-11-29 2002-06-06 Oculex Pharmaceuticals, Inc. Intraocular implants for preventing transplant rejection in the eye
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
DK1761266T3 (da) * 2004-05-25 2013-08-05 Galderma Pharma Sa Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
WO2008144399A1 (en) * 2007-05-18 2008-11-27 Bausch & Lomb Incorporated COMPLEXES COMPRISING α2-ADRENERGIC RECEPTOR AGONISTS AND COMPOSITIONS
PT2182960E (pt) * 2007-07-27 2014-06-11 Galderma Lab Inc Compostos, formulações e métodos para a redução das rugas, da flacidez e dos sulcos na pele
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
US8455548B2 (en) 2007-10-18 2013-06-04 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
US20110269805A1 (en) * 2007-10-18 2011-11-03 Gil Daniel W Method of treating sensorimotor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
DK2320911T3 (da) 2008-08-01 2014-11-03 Eye Therapies Llc Vasokonstriktionspræparater og fremgangsmåder til anvendelse deraf
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
WO2011028621A1 (en) * 2009-08-26 2011-03-10 Allergan, Inc. Method of treating compulsive disorders with alpha-2b adrenergic receptor agonists
NZ628266A (en) 2009-11-09 2016-02-26 Allergan Inc Compositions and methods for stimulating hair growth
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
WO2011075621A1 (en) * 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions and methods for ophthalmic delivery of nasal decongestants
JP5747392B2 (ja) 2010-03-26 2015-07-15 ガルデルマ・リサーチ・アンド・デヴェロップメント 毛細血管拡張症の安全かつ有効な治療のための改善された方法および組成物
AU2011231543B2 (en) 2010-03-26 2015-01-15 Galderma Research & Development Improved methods and compositions for safe and effective treatment of erythema
US20120073515A1 (en) * 2010-09-28 2012-03-29 Advanced Bionics Corporation Intrathecal needle guide apparatus
DK2444068T4 (en) 2010-10-21 2018-03-05 Galderma Sa Brimonide sub-composition
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
BR112014000634A2 (pt) 2011-07-14 2017-02-14 Allergan Inc métodos para tratamento de incontinência associada com atividade sexual
AU2014216112B2 (en) 2013-02-15 2019-02-21 Allergan, Inc. Sustained drug delivery implant
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
CA3006962A1 (en) * 2014-12-01 2016-06-09 Achelios Therapeutics Inc. Methods and compositions for treating migraine and conditions associated with pain
MX2021001645A (es) * 2018-08-29 2021-05-12 Cellix Bio Private Ltd Metodos y composiciones oftalmicas para el tratamiento de trastornos del ojo y enfermedades de la piel.
JP7534795B2 (ja) 2019-05-01 2024-08-15 クレキシオ バイオサイエンシーズ エルティーディー． そう痒症を治療する方法
CN120938924B (zh) * 2025-10-17 2025-12-16 杭州云柏医药科技有限公司 一种盐酸乌拉地尔注射液及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380754A (en) * 1988-02-29 1995-01-10 Virotex Corporation Topical composition enhancing healing of viral lesions
US6323204B1 (en) * 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
CA2173974C (en) * 1993-10-13 2006-05-02 James A. Burke Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US6462077B1 (en) * 1993-12-28 2002-10-08 Allergan, Inc. Thromboxane ligands without blood clotting side effects
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
WO1996025163A1 (en) 1995-02-14 1996-08-22 Board Of Supervisors Or Louisiana State Universityof Agricultural And Mechanical College Through Itsmedical Center Treatment of herpes simplex viruses
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
AU1827799A (en) 1997-12-15 1999-07-05 Axia Therapeutics, Inc. Oral delivery formulation
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
CA2340225A1 (en) 1998-10-27 2000-05-04 Wesley Wehsin Han Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap
AU768393B2 (en) * 1999-05-28 2003-12-11 Jeffrey Berlant Compounds and methods for the treatment of post traumatic stress disorder
AU5331200A (en) 1999-06-11 2001-01-02 Ohio State University Research Foundation, The Methods and compositions for treating raynaud's phenomenon and scleroderma
KR100331529B1 (ko) 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
IN188750B (enExample) 1999-12-04 2002-11-02 Khamar Bakulesh Dr Mafatlal
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6444681B1 (en) 2000-06-09 2002-09-03 The Ohio State University Research Foundation Methods and compositions for treating Raynaud's Phenomenon and scleroderma
WO2002005853A2 (en) * 2000-07-14 2002-01-24 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
JP2005529062A (ja) 2001-11-30 2005-09-29 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アデノシンａ１及びａ３受容体に特異的な化合物とその使用
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
DK1761266T3 (da) 2004-05-25 2013-08-05 Galderma Pharma Sa Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme

Similar Documents

Publication Publication Date Title
JP2012092123A5 (enExample)
JP2019516735A5 (enExample)
JP2014515013A5 (enExample)
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
JP2017537066A5 (enExample)
JP2013014622A5 (enExample)
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
FI3256218T3 (fi) Kdm1a-estäjät sairauksien hoidossa
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
HRP20180591T1 (hr) Inhibitori kinaze serina ili treonina
JP2013507408A5 (enExample)
CN110036005A (zh) 酰胺衍生物及其在药物中的应用
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
JP2014508753A5 (enExample)
WO2012099942A3 (en) Methods and compositions for treating metabolic syndrome
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
WO2014197345A3 (en) Imidazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
MA37455A1 (fr) Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique
JP2009537554A5 (enExample)
EA201300990A1 (ru) Парентеральное введение тапентадола
JP2015510916A5 (enExample)
WO2015000431A9 (zh) 替唑尼特氨基甲酸酯及其在药学中的应用
WO2015116856A3 (en) Farnesoid x receptor antagonists
EA201692298A1 (ru) Производные карбоксамидов